EMG
RCUS icon

ETF Managers Group’s Arcus Biosciences RCUS Stock Holding History

ETF Managers Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$257K Buy
+14,076
New +$269K 0.01% 562

Other funds holding RCUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ETF Managers Group's RCUS Position: Q1 2023 in Review

ETF Managers Group opened a new position in Arcus Biosciences (RCUS) in Q1 2023: 14,076 shares worth $257K. The stake represents 0.01% of the portfolio and ranks #562 among its holdings.

179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • ETF Managers Group held 14,076 shares of Arcus Biosciences worth $257K as of Q1 2023.
  • Arcus Biosciences was a new ETF Managers Group position in Q1 2023.
  • Arcus Biosciences made up 0.01% of ETF Managers Group's portfolio in Q1 2023, its #562 holding.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.